Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

Simeprevir MeSH Descriptor Data 2026


MeSH Heading
Simeprevir
Tree Number(s)
D02.886.590.700.700
D03.633.300.819
Unique ID
D000069616
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D000069616
Scope Note
Oral HCV-PROTEASE INHIBITOR effective against hepatitis C virus (HCV) serine protease NS3/4A. It is used in the treatment of chronic hepatitis C (Antivirals) genotype 1 infection in adults with compensated liver disease, including CIRRHOSIS.
Entry Term(s)
N-(17-(2-(4-isopropylthiazole-2-yl)-7-methoxy-8-methylquinolin-4-yloxy)-13-methyl-2,14-dioxo-3,13-diazatricyclo(13.3.0.04,6)octadec-7-ene-4-carbonyl)(cyclopropyl)sulfonamide
Olysio
TMC 435
TMC 435350
TMC-435
TMC-435350
TMC435
TMC435350
Pharm Action
Antiviral Agents
Protease Inhibitors
Registry Numbers
9WS5RD66HZ
0
Public MeSH Note
2016; SIMEPREVIR was indexed under SULFONAMIDES and HETEROCYCLIC COMPOUNDS, 3-RING 2008-2015
History Note
2016 (2008)
Date Introduced
2016/01/01
Last Updated
2016/05/31
Simeprevir Preferred
TMC 435350 Narrower
TMC 435 Narrower
Olysio Narrower
page delivered in 0.166s